A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
Clinical trial NCT06754501 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06754501
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-11
- Primary completion
- 2027-07-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.